Recombinant versus plasma-derived factor IX in the treatment of hemophilia B: proceedings of a meeting held in June 2003.
Mathew
Prasad
P
Ted R. Montoya Hemophilia Treatment Center, University of New Mexico School of Medicine, Albuquerque, USA. pmathew@salud.unm.edu
Altisent
Carmen
C
D016913:Blood Component Transfusion; D005164:Factor IX / Q000191:economics / Q000592:standards / Q000627:therapeutic use*; D002836:Hemophilia B / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D011292:Premedication; D011994:Recombinant Proteins / Q000627:therapeutic use; D018570:Risk Assessment
D011994:Recombinant Proteins; D005164:Factor IX